Medical/Pharmaceuticals
BON Launches AI-Powered New Drug Research and Development
XI'AN, China, July 30, 2025 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or "the Company"), a leading provider of bio-ingredient solutions for the natural health and personal care industries, today announced the official launch of its AI-driven drug research and development (R&D)...
Emerald Clinical Trials Confirms CEO Transition and Continuity Plan
SINGAPORE, July 30, 2025 /PRNewswire/ -- Emerald Clinical Trials, a leading global clinical research organization, today announced a leadership transition. Mary Gunn has stepped down effective immediately. The Board has appointedGlenn Kerkhof, a long-standing Board member and experienced CRO exec...
Dx&Vx Signs USD 220 Million Co-Development and License Agreement for mRNA Cancer Vaccine with U.S. Biotech Company
- First global out-licensing deal since founding — tangible return on new drug development investments - Significant milestone payments and future revenue expected — additional out-licensing of proprietary technologies anticipated SEOUL, South Korea, July 30, 2025 /PRNewswire/ -- Dx&Vx (DXVX) ha...
FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025: SNAP BENEFITS LINKED TO SLOWER COGNITIVE DECLINE, 10-YEAR STUDY FINDS
Key Takeaways * Participating in the Supplemental Nutrition Assistance Program (SNAP) may help protect against age-related cognitive decline, suggests an analysis of a national study. * Compared to non-participants, SNAP participants had a slower decline in cognitive function during the 10-y...
Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 29, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it will present Phase II ...
Telix H1 2025 Results: Investor Webcast Notification
MELBOURNE, Australia and INDIANAPOLIS, July 30, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that it will release its financial results for the half-year ended30 June 2025 on Thursday21 August 2025. An investor webcast and conference call wi...
Vexev and U.S. Renal Care Complete Enrollment in Groundbreaking Trial Evaluating Use of Robotic Ultrasound Scanning for AV Fistula Mapping in Dialysis Clinics
* CANSCAN study enrolled 120 patients with chronic kidney disease using the investigational, semi-autonomous VxWave™ Ultrasound Imaging System * The VxWave Ultrasound Imaging System potentially provides important insights into vascular access, to possibly enable earlier creation and use of AV...
FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025: ALZHEIMER'S ASSOCIATION RELEASES ITS FIRST CLINICAL PRACTICE GUIDELINE FOR BLOOD-BASED BIOMARKER TESTS
Key Takeaways * At AAIC 2025, the Alzheimer's Association released the first in a series of clinical practice guidelines for the diagnosis, treatment and care of Alzheimer's and all other dementia. * The guideline focuses on the use of blood-based biomarker tests by specialists to assess lev...
Alamar Biosciences and the German Center for Neurodegenerative Diseases (DZNE) partner for Landmark Proteomic Profiling study in the Rhineland Study Cohort
NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 to Power Biomarker Discovery in 23,000 Longitudinal Samples FREMONT, Calif., July 29, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced a strate...
Quasar Medical Unveils New Global Headquarters in Singapore
This move strategically enhances Quasar's ties to Singapore's MedTech ecosystem and facilitates closer collaboration with global partners SINGAPORE, July 29, 2025 /PRNewswire/ -- Quasar Medical, a global leader in manufacturing interventional and minimally invasive medical devices, announced tod...
Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress
PRINCETON, N.J. and TOKYO, July 29, 2025 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET IGNITE trial of rocatinlimab, an investigational therapy targeting the OX40 receptor (OX40R) in patients with moderate-to-severe atopic dermatitis (AD), wi...
Leo Cancer Care Receives FDA 510(k) Clearance for Marie® - A Revolutionary Upright Radiotherapy Platform
MIDDLETON, Wis., July 29, 2025 /PRNewswire/ -- Leo Cancer Care, a leader in upright radiotherapy solutions, today announces that its flagship product, Marie®, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Marie represents a paradigm shift in the delivery of part...
ArisGlobal Achieves Strong Global Growth and Continued Innovation in First Half 2025
Expanding Impact of LifeSphere® NavaX™ Across the Industry, 27 Go-Lives, and New Global Pharma Adoptions BOSTON, July 29, 2025 /PRNewswire/ -- ArisGlobal, an AI-first technology company and creator of LifeSphere®, today announced significant momentum in the first half of 2025, driven by continue...
Fapon to Debut Shine mT8000 Open-Access, High Throughput Clinical Chemistry and Immunoassay Analyzer at ADLM 2025
CHICAGO, July 29, 2025 /PRNewswire/ -- Fapon, a global leading life sciences company, will debut its Shine mT8000 Fully Automated Clinical Chemistry and Immunoassay System at the ADLM 2025 Annual Scientific Meeting. This launch marks a significant milestone in Fapon's commitment to building an op...
WuXi Biologics Singapore CRDMO Hub Advances with the Launch of Modular Drug Product Facility Fabrication
* Innovative modular design will accelerate construction and manufacturing timelines, enabling rapid adaptation of manufacturing capacities across diverse product formats. * Finished building will be one of the world's largest modular biologics Drug Product (DP) facilities, and will enhance W...
Tigermed Completes Acquisition of Japanese CRO Micron
HANGZHOU, China and TOKYO, July 29, 2025 /PRNewswire/ -- Tigermed (300347.SZ / 3347.HK), a leading global provider of clinical research solutions across the full lifecycle of global biopharmaceutical and medical device products, today announces the completion of its acquisition of CRO company Mic...
Alphamab Oncology Announces Anti-HER2 Biparatopic ADC JSKN003 Obtained Orphan Drug Designation from the U.S. FDA for the Treatment of GC/GEJ
SUZHOU, China, July 29, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of gastric cancer and ga...
FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025: U.S. POINTER STUDY SHOWS STRUCTURED LIFESTYLE PROGRAM TARGETING MULTIPLE RISK FACTORS IMPROVES COGNITION IN OLDER ADULTS AT RISK OF COGNITIVE DECLINE
Key Takeaways * Two lifestyle interventions in U.S. POINTER improved cognition in older adults at risk of cognitive decline. A structured intervention with more support and accountability showed greater improvement compared to a self-guided intervention. * In a large, representative group of...
Siemens Healthineers Receives Frost & Sullivan's 2025 North America Company of the Year Award for Excellence in Advanced Visualization Applications
Recognized for delivering diagnostic innovation, workflow efficiency, and enterprise imaging leadership through advanced visualization solutions SAN ANTONIO, July 28, 2025 /PRNewswire/ -- Frost & Sullivan is pleased to announce that Siemens Healthineers has been awarded the 2025 North America Co...
XellSmart Completed World's First Patient Dosing in its Registrational Clinical trial for iPSC-derived Subtype-specific Neural Cell Therapy for Spinal Cord Injury
SUZHOU, China, July 28, 2025 /PRNewswire/ -- XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd. achieved a significant milestone in its "world's first" China NMPA & US FDA-approved registrational clinical trial. This Phase I China registrational clinical trial for XS228 Cell Injection – the ...
Week's Top Stories
Most Reposted
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 328 media titles]
2026-02-24 12:00NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00Amadeus acquires SkyLink to accelerate the deployment of AI in travel
[Picked up by 310 media titles]
2026-02-26 19:57HBX Group and Traveloka expand strategic partnership to deepen APAC supply and accelerate global distribution
[Picked up by 309 media titles]
2026-02-26 09:30Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 302 media titles]
2026-02-24 16:13